ArticleBritish journal of cancer1999
Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumour tissue.
Article in British journal of cancer, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis.Oncotarget · 2017Pooled it
- Plasma S100β is a predictor for pathology and cognitive decline in Alzheimer's disease.Fluids and barriers of the CNS · 2025Article
- Article
- A microfluidic biosensor for the diagnosis of chronic wasting disease.Microsystems & nanoengineering · 2023Article
- Effects of Elemental Mercury Vapor Inhalation on Arterial Blood Gases, Lung Histology, and Interleukin-1 Expression in Pulmonary Tissues of Rats.TheScientificWorldJournal · 2021Article
- Prognostic significance of VEGF and components of the plasminogen activator system in endometrial cancer.Journal of cancer research and clinical oncology · 2020Article
- DNA Microsystems for Biodiagnosis.Micromachines · 2020Review
- The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer.Scientific reports · 2019Article
- Identification of novel serum autoantibodies against EID3 in non-functional pancreatic neuroendocrine tumors.Oncotarget · 2017Article
- High Expression of Urokinase-Type Plasminogen Activator Is Associated with Lymph Node Metastasis of Invasive Ductal Carcinoma of the Breast.Journal of breast cancer · 2016Article
- An ultra-sensitive immunoassay for quantifying biomarkers in breast tumor tissue.Journal of Cancer · 2014Article
- Evaluating the relationship between amyloid-β and α-synuclein phosphorylated at Ser129 in dementia with Lewy bodies and Parkinson's disease.Alzheimer's research & therapy · 2014Article
- Protein analytical assays for diagnosing, monitoring, and choosing treatment for cancer patients.Journal of healthcare engineering · 2012Article
- Development and validation of an immunoassay for quantification of topoisomerase I in solid tumor tissues.PloS one · 2012Article
- Influence of preoperative core biopsies on uPA/PAI-1 expression in breast cancer tissue.Virchows Archiv : an international journal of pathology · 2008Article
- The myofibroblast is the predominant plasminogen activator inhibitor-1-expressing cell type in human breast carcinomas.The American journal of pathology · 2003Article
- Expression of proteinases and inhibitors in human breast cancer progression and survival.Molecular pathology : MP · 2002Article
- High tPA-expression in primary melanoma of the limb correlates with good prognosis.British journal of cancer · 2000Article
- Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology.The American journal of pathology · 2000Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Enzyme-linked immunosorbent assay (ELISA) methods and immunohistochemistry (IHC) are techniques that provide information on protein expression in tissue samples. Both methods have been used to investigate the impact of the plasminogen activation (PA) system in cancer. In the present paper we first compared the expression levels of uPA, tPA, PAI-1 and uPAR in a compound group consisting of 33 cancer lesions of various origin (breast, lung, colon, cervix and melanoma) as quantitated by ELISA and semi-quantitated by IHC. Secondly, the same kind of comparison was performed on a group of 23 melanoma lesions and a group of 28 breast carcinoma lesions. The two techniques were applied to adjacent parts of the same frozen tissue sample, enabling the comparison of results obtained on material of almost identical composition. Spearman correlation coefficients between IHC results and ELISA results for uPA, tPA, PAI-1 and uPAR varied between 0.41 and 0.78, and were higher for the compound group and the breast cancer group than for the melanoma group. Although a higher IHC score category was always associated with an increased median ELISA value, there was an overlap of ELISA values from different scoring classes. Hence, for the individual tumour cases the relation between ELISA and IHC is ambiguous. This indicates that the two techniques are not directly interchangeable and that their value for clinical purposes may be different.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.